骨髓铁染色和铁蛋白对缺铁性贫血诊断价值研究.docVIP

骨髓铁染色和铁蛋白对缺铁性贫血诊断价值研究 　　摘要： 目的：观察缺铁性贫血患者的骨髓铁染色和铁蛋白变化，分析对比其结果意义，并探究骨髓铁染色和铁蛋白对缺铁性贫血诊断的具体价值。方法：对我院收治的50例缺铁性贫血患者与150例同期健康者采用全自动化学分析法、电化学发光法进行骨髓铁染色和铁蛋白检测，其中50例缺铁性贫血患者为实验组，150例同期健康者作为对照组，同时对其进行骨髓铁染色和铁蛋白结果分析，并评价其对缺铁性贫血诊断的价值。结果：在50例缺铁性贫血患者中，经过检测，其血清铁和铁蛋白以及骨髓细胞内外的铁含量明显低于健康组，差异有统计学意义（P0.05）。 结论：在缺铁性贫血的诊断中，骨髓铁染色结果和铁蛋白的检测结果都发挥指导作用，有效反映体内铁的贮存和利用情况，对临床诊断及鉴别具有很大的价值。 　　关键词：缺铁性贫血；血清铁蛋白；骨髓铁染色；诊断 　　Abstract： Objective：Observe the effects of thalidomide treatment of elderly patients and relapsed multiple myeloma clinical efficacy and effectiveness and safety， and to explore the most effective mechanism for the treatment of senile relapsed multiple myeloma.Method：clinical observation on 13 cases of primary treatment and 12 patients above 60 years of age with recurrent elderly myeloma patients， were made of arsenic trioxide combined with thalidomide treatment， intravenous arsenic trioxide for 10mg/d which， at the same time， the continuous injection 28 days， oral low dose thalidomide 100 200mmg/d， according to the actual situation of patients may be appropriate to increase， the maximum the limit is 300mg/d， 28 days for a course of treatment， taking two courses of treatment， efficacy and side effects were observed during the evaluation of curative effect， in accordance with the standard EBM T effect， according to the NCI CTCAECTCAE （National Cancer Institute Common Terminology Criteria for Adverse Events， version 3） standard to evaluate the adverse reaction.Result：in the 13 patients newly diagnosed 5 cases of partial remission （38.46%）， 5 cases of progress （38.46%）， and 3 cases ineffective （23.08%）. In 12 cases of senile multiple myeloma patients， 4 cases of partial remission （33.3%）， 5 cases （41%） had improvement， 3 cases （25%） are invalid， the total effective rate was 74.3%. Observed that， in the treatment of common adverse reactions are nausea and fatigue， abdominal distension and constipation， skin rash， liver injury， neutropenia， but after treatment will improve.Conclusion：Arsenic